Back to Search Start Over

Effect of Previous Anticoagulant Treatment on Risk of COVID-19.

Authors :
Zapata-Cachafeiro, Maruxa
Prieto-Campo, Ángela
Portela-Romero, Manuel
Carracedo-Martínez, Eduardo
Lema-Oreiro, Martina
Piñeiro-Lamas, María
Chaudhuri, Somnath
Salgado-Barreira, Ángel
Figueiras, Adolfo
Source :
Drug Safety; Mar2023, Vol. 46 Issue 3, p273-281, 9p
Publication Year :
2023

Abstract

Introduction: Little is known about the role played by anticoagulants in COVID-19. Objective: The aim of this study was to assess the impact of previous anticoagulant treatment on risk of hospitalization due to COVID-19, progression to severe COVID-19 and susceptibility to COVID-19 infection. Methods: We conducted a multiple population-based case–control study in northwest Spain, in 2020, to assess (1) risk of hospitalization: cases were all patients admitted due to COVID-19 with PCR confirmation, and controls were a random matched sample of subjects without a positive PCR; (2) progression: cases were hospitalized COVID-19 subjects, and controls were all non-hospitalized COVID-19 patients; and (3) susceptibility: cases were patients with a positive PCR (hospitalized and non-hospitalized), and the controls were the same as for the hospitalization model. Adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using a generalized linear mixed model. Results: The consumption of antivitamin K and direct-acting anticoagulants apparently was not associated with the risk of progression to severe COVID-19 (OR 0.93 [95% CI 0.74–1.17] and OR 1.04 [95% CI 0.79–1.36], respectively). Antivitamin K anticoagulants were associated with a significantly lower risk of hospitalization (OR 0.77 [95% CI 0.64–0.93]), which, in part, can be explained by a decreased risk of susceptibility to infection (OR 0.83 [95% CI 0.74–0.92]). The use of direct-acting anticoagulants was not associated with the risk of hospitalization, although it also seems to decrease susceptibility (OR 0.85 [95% CI 0.74–0.98]). It has also been observed that low-molecular-weight heparins were associated with an increased risk of progression to severe COVID-19 (OR 1.25 [95% CI 1.01–1.55]). Conclusion: The results of this study have shown that antivitamin K anticoagulants and direct-acting anticoagulants do not increase the risk of progression to more severe stages. Antivitamin K consumption was associated with a lower risk of hospitalization and susceptibility to infection. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01145916
Volume :
46
Issue :
3
Database :
Complementary Index
Journal :
Drug Safety
Publication Type :
Academic Journal
Accession number :
162260768
Full Text :
https://doi.org/10.1007/s40264-022-01266-0